Glonghui, May 23 | Hebo Pharmaceuticals (2142.HK) bucked the trend and surged nearly 18% to HK$1.65 at the beginning of the session. The stock price hit a new high since March 14. According to the news, Nona Biotech, a wholly-owned subsidiary of Harbour BioMed, announced today that it has reached a licensing agreement with AstraZeneca for a preclinical monoclonal antibody project to accelerate the development of targeted cancer therapies. Under the agreement, Nona Biotech will receive a down payment of $19 million upon completion of the transaction, and is entitled to an anticipated recent milestone payment of $10 million, as well as up to $575 million in development, regulatory and commercial milestone payments and tiered royalties based on net sales. Additionally, if AstraZeneca exercises its right to choose, Nona Biotech will receive further related payments.
港股异动丨和铂医药逆势涨近18%创逾2个月新高，与阿斯利康就单克隆抗体项目达成许可协议
Changes in Hong Kong stocks 丨 Heplatinum Pharmaceuticals bucked the trend and reached a new high of more than 2 months, reaching a licensing agreement with AstraZeneca on a monoclonal antibody project
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.